Cardiovascular diseases, particularly heart attacks and strokes, cause the death of about seventeen million people worldwide annually. In the US alone, around five million people suffer from heart problems.
In heart valve market, mechanical valves are more durable than tissue heart valves but require an anticoagulant. With technological advancements, the issue of durability has been resolved and hence, the market has moved towards tissue valves. Tissue valve represent about three-fifth of the total valve market.
Tissue valve market is dominated by Edwards Lifesciences. The surgical heart valve therapy segment represents about half of Edwards’ turnover. Medtronic and St. Jude Medical are the other major players. St. Jude Medical is the leader in mechanical heart valves. St. Jude has been successfully trying to convert its mechanical valve users to tissue valves and thus increasing its market share. St. Jude entered the U.S. tissue valve industry about 2-3 years back, and thereafter, Edwards’s growth has slowed down.
The report is aimed at providing a basic understanding of the heart valve market. It analyzes the worldwide and US market. Apart from providing a competitive landscape of the market, the report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major technological developments in the heart valve market.